Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Trial Profile

A Phase 2, Multi-Center, Randomized, Double-Blind, Placebo Controlled Parallel-Group Study to Evaluate the Clinical Efficacy and Safety of Induction Therapy With RPC1063 in Patients With Moderately to Severely Active Ulcerative Colitis

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 01 Dec 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ozanimod (Primary)
  • Indications Ulcerative colitis
  • Focus Therapeutic Use
  • Acronyms TOUCHSTONE
  • Sponsors Celgene Corporation; Celgene International SARL; Receptos
  • Most Recent Events

    • 17 Oct 2023 Results of a pooled analysis assessing tolerability and safety of long-term ozanimod treatment from following clinical studies: NCT01647516, NCT02435992, NCT02531126 and NCT02576717 presented at the 31st United European Gastroenterology Week
    • 27 Apr 2023 Results assessing tolerability/safety of extended ozanimod 0.92 mg/day treatment in adults with relapsing multiple sclerosis (RMS) or moderately to severely active ulcerative colitis, presented at the 75th Annual Meeting of the American Academy of Neurology 2023.
    • 27 Oct 2021 Results (n=1158; data cut off date: September 30, 2020) of pooled analysis from UC studies phase 2 and phase 3 assessing the safety of extended exposure to ozanimod HCl 1 mg/day from the Ulcerative Colitis and Relapsing Multiple Sclerosis clinical trials presented at the American College of Gastroenterology Annual Scientific Meeting and Postgraduate Course 2021
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top